Leaders bring more than 45 years of sales and marketing leadership to the company
REDMOND, Wash.–(BUSINESS WIRE)–EndoGastric® Solutions, Inc. (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today the addition of two senior executives to its leadership team: Martin Reid, Vice President of Sales, and Ted Stephens, Vice President of Marketing and Professional Education.
In their respective roles, Reid and Stephens will focus on meeting increased commercial demand of the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure using EsophyX® technology, a minimally-invasive procedure for the treatment of GERD. An estimated 1 in 5 Americans suffer from GERD, or weekly heartburn and/or regurgitation.1
“With EndoGastric Solutions on a path of rapid growth, the addition of these highly experienced commercial leaders is a critical component of our ongoing commercial strategy,” said Skip Baldino, President and CEO, EndoGastric Solutions. “Both Ted and Martin bring a deep understanding of the health care industry and are committed to making the TIF procedure a core component of physicians’ treatment approach to GERD patients across the country and abroad.”
Martin Reid, Vice President of Sales
With more than 25 years of experience in health care, Reid has held a variety of positions in sales, leadership and business development throughout his career. He most recently served as Area Vice President at Olympus Corporation of the Americas. Prior to that, Reid has served as National Sales Manager at Johnson & Johnson, Sedasys; Director of Sales at Xenex Disinfection Services; Regional Sales Manager at Given Imaging (acquired by Medtronic GI Solutions); President of his own medical device consulting practice, Reid Agency; National Sales Manager at NeoPath, Inc.; and Regional Sales Manager at Boston Scientific Corporation. He began his career with Johnson & Johnson in the Ethicon division after graduating from Whitworth University with a Bachelor of Arts degree in business management.
Ted Stephens, Vice President of Marketing and Professional Education
Stephens brings over 20 years of diverse commercial leadership across global markets in the medical device industry, with extensive knowledge in both minimally-invasive surgery and therapeutic gastrointestinal markets. Stephens most recently served as Director of Marketing for NOVADAQ Technologies. Prior to that he was the Vice President of Global Marketing at Apollo Endosurgery where he led a global team to develop and execute marketing strategies for a portfolio of surgical and therapeutic GI products. He also spent 16 years at Ethicon Endo-Surgery with various positions in engineering, sales, sales leadership and marketing. Stephens earned his Master’s degree in Business Administration from Xavier University and a Bachelor of Science in engineering from Michigan State University.
For more information on EndoGastric Solutions and to find additional career opportunities, visit www.endogastricsolutions.com.
About Current Procedural Terminology (CPT®)
CPT codes are a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services. The coding serves as an effective way to provide communication among healthcare providers, patients and third parties. CPT is registered trademark of the American Medical Association.
The Federal Register posts coding and payment information specific to the CPT code, allowing patients to receive access to treatment more easily for GERD. Physicians and hospitals can reference CPT Code 43210 EGD esophagogastric fundoplasty and APC 5331 Complex GI Procedures for TIF® procedures.
Gastroesophageal reflux disease (GERD) is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. In the U.S., GERD is the most common gastrointestinal-related diagnosis physicians make during clinical visits. Pain and discomfort from acid reflux impact more than 80 million Americans at least once a month according to estimates. The first treatment recommendations for GERD patients is to make lifestyle changes (e.g., diet, scheduled eating times and sleeping positions). Patients are instructed to take prescription medications; unfortunately, it is a common practice to increase medication doses and, over time, become dependent on these medications to control symptoms. A variety of other health complications are linked to the long-term, maximum-dose usage of prescription medications.
About Transoral Incisionless Fundoplication (TIF®) procedure for reflux
Performed without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical repair an effective treatment option to correct the underlying cause of GERD. Most patients stopped using daily medications to control symptoms and had their esophageal inflammation (esophagitis) eliminated up to three years after the TIF procedure based on studies.
There are more than 20,000 TIF patients treated worldwide since the EsophyX® device launched. In the past ten years, over 60 centers published more than 80 peer-reviewed papers. These studies document consistent outcomes on over 1,300 unique study patients. For more information, visit www.GERDHelp.com.
About EsophyX® technology
The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids refluxing back into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope. The U.S. Food and Drug Administration cleared the original EsophyX device in 2007. EndoGastric Solutions® launched the third generation EsophyX device, the EsophyX Z model, in 2015. The evolving EsophyX technology now enables surgeons and gastroenterologists to use a wider selection of endoscopes to treat the underlying anatomical cause of GERD. These options include low profile and larger high-definition models.
The EsophyX device with SerosaFuse® fasteners and accessories are indicated for use in transoral tissue approximation, full thickness plication and ligation in the gastrointestinal tract. They are indicated for the treatment of symptomatic chronic GERD in patients who require and respond to pharmacological therapy. The device is also indicated to narrow the gastroesophageal junction, and reduce hiatal hernia ≤ 2cm in size in patients with symptomatic chronic GERD. Patients with hiatal hernias larger than 2cm may be included, when a laparoscopic hiatal hernia repair reduces the hernia to 2cm or less.
About EndoGastric Solutions®
Based in Redmond, WA, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. Join the conversation on Twitter: @GERDHelp Facebook: GERDHelpcom and Google+: GERDHelp.
1. El-Serag H. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 June; 63(6): 871–880.